TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.86 USD
-0.01 (-0.53%)
Updated Apr 26, 2024 03:52 PM ET
After-Market: $1.88 +0.02 (1.08%) 6:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for TherapeuticsMD, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 49 | 65 | 80 | 161 |
Receivables | 3 | 0 | 36 | 32 | 24 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 8 | 8 | 12 |
Other Current Assets | 4 | 6 | 11 | 8 | 11 |
Total Current Assets | 12 | 55 | 119 | 128 | 208 |
Net Property & Equipment | 0 | 0 | 1 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 18 | 20 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 6 | 7 | 40 | 41 | 44 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 43 | 90 | 169 | 182 | 266 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 20 | 21 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 188 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 19 | 44 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 26 | 0 | 38 | 34 |
Total Current Liabilities | 7 | 47 | 253 | 59 | 53 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 238 | 195 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 2 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 55 | 263 | 306 | 257 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 979 | 975 | 957 | 755 | 704 |
Retained Earnings | -950 | -939 | -1,051 | -879 | -695 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 35 | -94 | -124 | 9 |
Total Liabilities & Shareholder's Equity | 43 | 90 | 169 | 182 | 266 |
Total Common Equity | 29 | 35 | -94 | -124 | 9 |
Shares Outstanding | 10.50 | 9.40 | 8.40 | 6.00 | 5.40 |
Book Value Per Share | 2.79 | 3.74 | -11.15 | -20.67 | 1.70 |
Fiscal Year End for TherapeuticsMD, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 10 | 14 | 17 |
Receivables | NA | 3 | 3 | 1 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 5 | 5 | 5 |
Total Current Assets | NA | 12 | 17 | 20 | 25 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 18 | 19 | 20 | 20 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 6 | 7 | 7 | 7 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 43 | 50 | 54 | 60 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 1 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 3 | 7 | 11 | 14 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 7 | 1 | 3 |
Total Current Liabilities | NA | 7 | 15 | 14 | 19 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 14 | 22 | 22 | 28 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 979 | 977 | 977 | 975 |
Retained Earnings | NA | -950 | -949 | -945 | -943 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 29 | 28 | 31 | 32 |
Total Liabilities & Shareholder's Equity | NA | 43 | 50 | 54 | 60 |
Total Common Equity | 0 | 29 | 28 | 31 | 32 |
Shares Outstanding | 11.50 | 10.50 | 10.50 | 10.10 | 10.10 |
Book Value Per Share | 0.00 | 2.79 | 2.67 | 3.09 | 3.17 |